CLDX

MKT CAP:$2B

Celldex Therapeutics, Inc.

Market Cap

$2B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$34.25+$7.24 (+26.80%)

Apr 21, 2026

Company Details

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients...

CEO

Anthony S. Marucci

IPO Date

May 15, 1986

Website

www.celldex.com

Key Metrics TTM

Revenue

$2M

-78.6% YoY

Net Income

-$259M

EPS (Diluted)

-$3.90

Free Cash Flow

-$213M

Revenue / Share

$0.02

Gross Margin

100.0%

Operating Margin

-19160.0%

Net Margin

-17253.3%

FCF Margin

-14224.7%

P/S

1474.4x

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Feb 25, 2026

$2M-78.6%EPS -$3.90

Q4 2025

Feb 25, 2026

$75.0K-93.6%EPS -$1.23

Q3 2025

Nov 10, 2025

$0-100.0%EPS -$1.01

Q2 2025

Aug 7, 2025

$730.0K-70.8%EPS -$0.85

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$174.0K	-$17M	-$23M
Q2 22	$163.0K	-$21M	-$36M
Q3 22	$407.0K	-$21M	-$28M
Q4 22	$2M	-$21M	-$28M
Q1 23	$967.0K	-$26M	-$32M
Q2 23	$268.0K	-$26M	-$33M
Q3 23	$2M	$750.0K	-$41M
Q4 23	$4M	-$26M	-$48M
Q1 24	$156.0K	-$619.0K	-$41M
Q2 24	$2M	$2M	-$46M
Q3 24	$3M	$3M	-$52M
Q4 24	$1M	$356.0K	-$56M
Q1 25	$695.0K	$695.0K	-$63M
Q2 25	$730.0K	$730.0K	-$64M
Q3 25	$0	$0	-$74M
Q4 25	$75.0K	$75.0K	-$87M

Valuation

Quarter	P/S	P/E
Q1 22	534.1x	—
Q2 22	2684.0x	—
Q3 22	2051.6x	—
Q4 22	938.3x	—
Q1 23	702.1x	—
Q2 23	679.4x	—
Q3 23	506.7x	—
Q4 23	321.3x	—
Q1 24	364.2x	—
Q2 24	266.4x	—
Q3 24	221.7x	—
Q4 24	315.0x	—
Q1 25	292.6x	—
Q2 25	381.9x	—
Q3 25	850.6x	—
Q4 25	1474.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$25M	-$25M
Q2 22	-$22M	-$23M
Q3 22	-$35M	-$36M
Q4 22	-$22M	-$22M
Q1 23	-$29M	-$29M
Q2 23	-$27M	-$28M
Q3 23	-$19M	-$19M
Q4 23	-$33M	-$33M
Q1 24	-$41M	-$41M
Q2 24	-$29M	-$30M
Q3 24	-$55M	-$55M
Q4 24	-$32M	-$33M
Q1 25	-$54M	-$55M
Q2 25	-$44M	-$45M
Q3 25	-$49M	-$49M
Q4 25	-$64M	-$65M

Capital Expenditures

Quarter	CapEx
Q1 22	$575.0K
Q2 22	$673.0K
Q3 22	$345.0K
Q4 22	$235.0K
Q1 23	$585.0K
Q2 23	$410.0K
Q3 23	$157.0K
Q4 23	$666.0K
Q1 24	$344.0K
Q2 24	$274.0K
Q3 24	$618.0K
Q4 24	$756.0K
Q1 25	$265.0K
Q2 25	$728.0K
Q3 25	$440.0K
Q4 25	$993.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-74.6%	+35.3%
Q2 22	-95.3%	+116.1%
Q3 22	+166.0%	+34.0%
Q4 22	+382.9%	+42.7%
Q1 23	+455.7%	+42.7%
Q2 23	+64.4%	-8.4%
Q3 23	+272.7%	+52.1%
Q4 23	+156.1%	+75.5%
Q1 24	-83.9%	+21.9%
Q2 24	+832.1%	+45.8%
Q3 24	+110.3%	+29.4%
Q4 24	-71.6%	+10.5%
Q1 25	+345.5%	+55.6%
Q2 25	-70.8%	+32.3%
Q3 25	-100.0%	+33.1%
Q4 25	-93.6%	+52.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$3M	1812.1%
Q2 22	$3M	2119.0%
Q3 22	$4M	1104.7%
Q4 22	$5M	279.5%
Q1 23	$4M	448.8%
Q2 23	$5M	1946.6%
Q3 23	$7M	469.4%
Q4 23	$7M	174.6%
Q1 24	$7M	4616.7%
Q2 24	$8M	305.8%
Q3 24	$10M	301.5%
Q4 24	$10M	832.3%
Q1 25	$9M	1340.4%
Q2 25	$9M	1259.0%
Q3 25	$9M	—
Q4 25	$9M	11878.7%

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$17M	$7M
Q2 22	$21M	$7M
Q3 22	$22M	$7M
Q4 22	$23M	$7M
Q1 23	$27M	$7M
Q2 23	$26M	$7M
Q3 23	$35M	$8M
Q4 23	$30M	$9M
Q1 24	$31M	$9M
Q2 24	$39M	$9M
Q3 24	$3.0K	$10M
Q4 24	$46M	$10M
Q1 25	$53M	$11M
Q2 25	$54M	$10M
Q3 25	$63M	$11M
Q4 25	$75M	$12M

Revenue Segments

Quarter	Contracts and grants	Product development and licensing agreements	Grant	Service
Q1 22	$144.0K	$30.0K	—	—
Q2 22	$163.0K	—	—	—
Q3 22	$407.0K	—	—	—
Q4 22	—	—	$2M	$26.0K
Q1 23	—	—	$967.0K	—
Q2 23	—	—	$252.0K	$16.0K
Q3 23	—	—	$2M	$2.0K
Q1 24	—	—	$154.0K	$2.0K
Q2 24	—	—	$2M	$2.0K
Q3 24	—	—	$3M	$3.0K
Q1 25	—	—	$645.0K	$50.0K
Q2 25	—	—	$723.0K	$7.0K
Q3 25	—	—	$1M	$57.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$25M	$355M	$380M
Q2 22	$28M	$328M	$357M
Q3 22	$19M	$305M	$323M
Q4 22	$29M	$276M	$305M
Q1 23	$54M	$224M	$278M
Q2 23	$28M	$224M	$253M
Q3 23	$21M	$214M	$235M
Q4 23	$35M	$387M	$422M
Q1 24	$115M	$709M	$824M
Q2 24	$43M	$760M	$802M
Q3 24	$36M	$720M	$756M
Q4 24	$28M	$697M	$725M
Q1 25	$17M	$656M	$673M
Q2 25	$23M	$607M	$630M
Q3 25	$36M	$547M	$583M
Q4 25	$29M	$490M	$519M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	47M	+0.1%	+18.0%
Q2 22	47M	+0.0%	+18.0%
Q3 22	47M	+0.3%	+3.2%
Q4 22	47M	+0.5%	+0.9%
Q1 23	47M	+0.2%	+1.0%
Q2 23	47M	+0.1%	+1.1%
Q3 23	47M	+0.0%	+0.7%
Q4 23	52M	+10.1%	+10.4%
Q1 24	59M	+13.2%	+24.7%
Q2 24	66M	+12.1%	+39.7%
Q3 24	66M	+0.4%	+40.3%
Q4 24	66M	+0.1%	+27.5%
Q1 25	66M	+0.0%	+12.8%
Q2 25	66M	+0.0%	+0.6%
Q3 25	66M	+0.0%	+0.2%
Q4 25	67M	+0.1%	+0.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$1.3K	134
Q2 22	$1.2K	134
Q3 22	$3.0K	134
Q4 22	$10.9K	148
Q1 23	$6.5K	148
Q2 23	$1.8K	148
Q3 23	$10.3K	148
Q4 23	$25.8K	160
Q1 24	$975	160
Q2 24	$15.6K	160
Q3 24	$19.9K	160
Q4 24	$6.3K	186
Q1 25	$3.7K	186
Q2 25	$3.9K	186
Q3 25	$0	186
Q4 25	$379	198

Revenue / Employee